GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inozyme Pharma Inc (NAS:INZY) » Definitions » Degree of Financial Leverage

Inozyme Pharma (Inozyme Pharma) Degree of Financial Leverage : -2.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inozyme Pharma Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Inozyme Pharma's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was -2.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Inozyme Pharma's Degree of Financial Leverage or its related term are showing as below:

INZY's Degree of Financial Leverage is ranked better than
93.87% of 1501 companies
in the Biotechnology industry
Industry Median: 0.96 vs INZY: -2.00

Inozyme Pharma Degree of Financial Leverage Historical Data

The historical data trend for Inozyme Pharma's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inozyme Pharma Degree of Financial Leverage Chart

Inozyme Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial 2.30 0.75 59.24 0.38 69.03

Inozyme Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.96 -3.90 -5.72 69.03 -2.00

Competitive Comparison of Inozyme Pharma's Degree of Financial Leverage

For the Biotechnology subindustry, Inozyme Pharma's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inozyme Pharma's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inozyme Pharma's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Inozyme Pharma's Degree of Financial Leverage falls into.



Inozyme Pharma Degree of Financial Leverage Calculation

Inozyme Pharma's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -1.37 (Mar. 2024) / -1.58 (Mar. 2023) - 1 )/( -71.489 (Mar. 2024) / -67.036 (Mar. 2023) - 1 )
=-0.1329/0.0664
=-2.00***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Inozyme Pharma  (NAS:INZY) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Inozyme Pharma Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Inozyme Pharma's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Inozyme Pharma (Inozyme Pharma) Business Description

Traded in Other Exchanges
N/A
Address
321 Summer Street, Suite 400, Boston, MA, USA, 02210
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Executives
Robert Lorne Hopfner director, 10 percent owner C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Pivotal Bioventure Partners Fund I G.p., L.p. director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I U.g.p. Ltd director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I, L.p. director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Matthew Winton officer: COO C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Sanjay Subramanian officer: SVP, CFO 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Henric Bjorn Bjarke officer: See Remarks ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Axel Bolte director, 10 percent owner, officer: See Remarks PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Inozyme Pharma, Inc. director 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Deborah Wenkert officer: SVP, CMO C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Scott D Sandell 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025